Marshall SR (June 2006). "Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?". Nature Clinical Practice. Oncology. 3 (6). Nature Publishing: 302–314. doi:10.1038/ncponc0511. PMID16757968. S2CID8441159.
Fahmy IR, Abu-Shady H (1947). "Ammi majus Linn.; pharmacognostical study and isolation of a crystalline constituent, ammoidin". Quarterly Journal of Pharmacy and Pharmacology. 20 (3): 281–91, discussion 426. PMID20273299.
Marshall SR (June 2006). "Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?". Nature Clinical Practice. Oncology. 3 (6). Nature Publishing: 302–314. doi:10.1038/ncponc0511. PMID16757968. S2CID8441159.
semanticscholar.org
api.semanticscholar.org
Marshall SR (June 2006). "Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?". Nature Clinical Practice. Oncology. 3 (6). Nature Publishing: 302–314. doi:10.1038/ncponc0511. PMID16757968. S2CID8441159.